Regdanvimab
drugOn this page
Also known as Ct-p59CTP-59CTP59Regkirona
Summary
Regdanvimab (CHEMBL4650462) is an approved antibody (ATC J06BD06); indicated across 1 condition including covid-19.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: J06BD06
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650462 |
| Name | Regdanvimab |
| Type | Antibody |
| Max phase | 4 |
| ATC | J06BD06 |
Also known as: Ct-p59, CT-P59, CTP-59, CTP59, Regdanvimab, Regkirona, REGDANVIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CoV Spike glycoprotein | Binding | 10.57 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| COVID-19 | 4 | MONDO:0100096 | MONDO:0100096 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05982704 | PHASE4 | UNKNOWN | Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19 |
| NCT04602000 | PHASE2/PHASE3 | COMPLETED | A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection |
| NCT04525079 | PHASE1 | COMPLETED | To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects |
| NCT04593641 | PHASE1 | COMPLETED | This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: COVID-19